^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CXCL10 elevation

    i
    Other names: CXCL10, C7, crg-2, gIP-10, IFI10, INP10, IP-10, mob-1, SCYB10, Chemokine (C-X-C motif) ligand 10
    Entrez ID:
    3627
    Related biomarkers:
    Expression
    Others
    2ms
    PD-1 and CTLA-4 serve as major gatekeepers for effector and cytotoxic T-cell potentiation by limiting a CXCL9/10-CXCR3-IFNγ positive feedback loop. (PubMed, Front Immunol)
    This may explain why patients that are CXCL9/CXCL10high tend to respond well to anti-PD-1 therapy, as opposed to patients that are CXCL9/CXCL10low. It also suggests a therapeutic role for CXCL9-Fc or CXCL10-Fc therapy; herein we demonstrate significant anti-tumor activity in multiple murine tumor models with such agents.
    Journal
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CD4 (CD4 Molecule) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • CXCR3 (C-X-C Motif Chemokine Receptor 3)
    |
    CXCL10 elevation
    3ms
    Construction of self-driving anti-αFR CAR-engineered NK cells based on IFN-γ and TNF-α synergistically induced high expression of CXCL10. (PubMed, Neoplasia)
    This study confirmed that IFN-γ and TNF-α secreted by αFR-CAR-engineered NK cells can synergistically induce high expression of CXCL10 in ovarian cancer cells and constructed self-driving αFR-CAR-engineered NK cells that can break through migration barriers based on CXCL10, which may provide a new therapeutic weapon for ovarian cancer.
    Journal
    |
    FOLR1 ( Folate receptor alpha ) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • JAK1 (Janus Kinase 1) • STAT1 (Signal Transducer And Activator Of Transcription 1)
    |
    CXCL10 elevation • CXCL10 expression
    1year
    Serum CXCL10 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced BCLC stage C hepatocellular carcinoma: A multicenter analysis. (PubMed, Cancer Med)
    Serum CXCL10-2c levels were predictive of Atez/Bev efficacy in patients with BCLC stage C HCC.
    Journal • Metastases
    |
    CXCL10 (Chemokine (C-X-C motif) ligand 10)
    |
    CXCL10 elevation
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    almost2years
    CXCL10 is a prognostic marker for pancreatic adenocarcinoma and tumor microenvironment remodeling. (PubMed, BMC Cancer)
    CXCL10 is a potential prognostic marker for PAAD and provide additional insights into the treatment of PAAD based on TME transformation. However, more independent experimentation with the CXCL10 is need.
    Journal
    |
    CXCL10 (Chemokine (C-X-C motif) ligand 10)
    |
    CXCL10 elevation
    almost2years
    Elevated CXCL10:IL-8 ratio in bronchoalveolar lavage fluid of immune checkpoint inhibitor-related pneumonitis (ELCC 2023)
    Conclusions Bulk cytokine profiling identifies a high CXCL10: IL-8 ratio as a reproducible characteristic of ICI-pneumonitis BALF, in line with immunophenotypic data suggesting an interferon-γ driven immune response and absence of neutrophilic inflammation, respectively. The diagnostic utility of the CXCL10: IL-8 ratio in BALF to identify ICI-pneumonitis should be further investigated.
    Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • CCL4 (Chemokine (C-C motif) ligand 4) • CCL2 (Chemokine (C-C motif) ligand 2) • CSF2 (Colony stimulating factor 2) • GZMB (Granzyme B) • IL17A (Interleukin 17A) • CXCR1 (Chemokine (C-X-C motif) receptor 1) • IL13 (Interleukin 13) • IL15 (Interleukin 15) • IL4 (Interleukin 4) • IL5 (Interleukin 5) • IL7 (Interleukin 7)
    |
    CXCL8 elevation • CXCL10 elevation
    almost3years
    Cxcl10 chemokine induces migration of ING4-deficient breast cancer cells via a novel crosstalk mechanism between the Cxcr3 and Egfr receptors. (PubMed, Mol Cell Biol)
    Taken together, these results presented a novel mechanism of Cxcl10 that elicits migration of ING4-deleted cells, in part by inducing a physical or proximal association between Cxcr3 and Egfr and signaling downstream via Gβγ. These results further indicated that ING4 plays a critical role in the regulation of Cxcl10 signaling that enables breast cancer progression.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCR3 (C-X-C Motif Chemokine Receptor 3)
    |
    CXCL10 elevation
    almost3years
    High Expression of Interferon Pathway Genes CXCL10 and STAT2 Is Associated with Activated T-Cell Signature and Better Outcome of Oral Cancer Patients. (PubMed, J Pers Med)
    GSEA of oral cancers stratified by CXCL10/STAT2 expression showed that activation of T-cell pathways and increased tumor infiltration scores of Type 1 T helper (Th1) and CD8+ T cells were associated with high CXCL10/STAT2 expression. These results suggest that high CXCL10/STAT2 expression can predict a favorable outcome in oral cancer patients.
    Journal
    |
    CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • STAT2 (Signal transducer and activator of transcription 2)
    |
    CXCL10 elevation • STAT2 expression
    over3years
    Identification of CXCL10-Relevant Tumor Microenvironment Characterization and Clinical Outcome in Ovarian Cancer. (PubMed, Front Genet)
    This work proposed a promising biomarker for evaluating TME immune characteristics and clinical outcomes in patients with ovarian cancer. Estimation of CXCL10 risk pattern sheds a novel insight on ovarian cancer TME immune characteristics and provides strategies for ovarian cancer immunotherapy.
    Clinical • Clinical data • Journal • IO biomarker
    |
    CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • IL2 (Interleukin 2)
    |
    CXCL10 elevation • CXCL9 expression